Quick Answer
LEXICON PHARMACEUTICALS, INC. reported Cash and Equivalents of $34.33 million for fiscal year 2025.
LEXICON PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $34.33M | -48.5% |
| 2024 | $66.66M | +196.7% |
| 2023 | $22.46M | -51.5% |
| 2022 | $46.34M | -27.7% |
| 2021 | $64.06M | -49.3% |
| 2020 | $126.26M | +249.6% |
| 2019 | $36.11M | -55.1% |
| 2018 | $80.39M | +30.4% |
| 2017 | $61.66M | +32.3% |
| 2016 | $46.60M | -77.0% |
| 2015 | $202.99M | +47.9% |
| 2014 | $137.27M | +266.1% |
| 2013 | $37.50M | +23.3% |
| 2012 | $30.42M | -83.7% |
| 2011 | $186.31M | +294.7% |
| 2010 | $47.21M | -53.1% |
| 2009 | $100.55M | +17.1% |
| 2008 | $85.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $49.66M | +43.7% | +132.4% |
| June 30, 2025 | $21.36M | -40.0% | -66.0% |
| March 31, 2025 | $62.89M | -34.8% | -5.7% |
| December 31, 2024 | $66.66M | +196.7% | +92.9% |
| September 30, 2024 | $34.55M | +63.6% | -3.0% |
| June 30, 2024 | $35.62M | -65.2% | -63.1% |
| March 31, 2024 | $96.49M | +271.1% | +329.5% |
| December 31, 2023 | $22.46M | -51.5% | +6.4% |
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -48.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, LEXICON PHARMACEUTICALS, INC.’s cash and equivalents has declined by 60.0% (from $85.87 million to $34.33 million).
- The most recent figure is from LEXICON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: